New hope for myeloma patients with kidney failure: targeted drug tested in dialysis patients
NCT ID NCT04398745
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that targets a protein on myeloma cells to deliver a cancer-killing agent. The goal is to see how the drug behaves in the body and whether it is safe in people with different levels of kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin
What this could lead to
If successful, this study could show that belantamab mafodotin is safe and works similarly in people with kidney problems, expanding treatment options for this group.
What could go wrong
This is a small, early-phase study focused on safety and drug levels, not on proving the drug works. Kidney impairment may affect how the drug is processed, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Athens, 10676, Greece
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Busan, 49241, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea